Patient-Reported Outcomes (Pros) With First-Line (1L) Cemiplimab In Patients With Locally Advanced Non-Small Cell Lung Cancer (Lansclc): EMPOWER-Lung 1 Subpopulation

No Thumbnail Available

Files

73.pdf (127.4 KB)

Date

2022

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

https://reader.elsevier.com/reader/sd/pii/S0923753422002551?token=F81D614EB86BFF60216085822CE147E22A08EBDDCDE1049DF36DF115BD81C19835D4791709D44FF7BF0D47AEB4A5C1CB&originRegion=eu-west-1&originCreation=20221201121105
 http://hdl.handle.net/11727/8196

Collections

Tıp Fakültesi / Faculty of Medicine
Wos Açık Erişimli Yayınlar
Wos İndeksli Yayınlar Koleksiyonu

Endorsement

Review

Supplemented By

Referenced By